Research Output Journal of Engineering and Scientific Research 4(3): 107-112, 2025

ROJESR Publications Online ISSN: 1115-9790

https://rojournals.org/roj-engineering-and-scientific-research/ Print ISSN: 1115-6155

https://doi.org/10.59298/ROJESR/2025/4.3.107112

Long-Term Immune Programming through Early-Life Immunotherapies: Risks and Benefits

Zikayo Amulaga R.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Early-life immunotherapies represent a transformative approach to enhancing immune resilience by targeting critical windows of immune system development. During infancy and early childhood, the immune system exhibits heightened plasticity, allowing external interventions to imprint lasting immunological effects. Vaccines, monoclonal antibodies, cytokine modulators, and microbiome-directed therapies are among the immunotherapeutic strategies increasingly applied in early life to prevent infectious diseases and modulate immune-mediated conditions. These interventions have demonstrated significant benefits, including reduced morbidity and mortality from infections, mitigation of allergic disease onset, and potential prevention of autoimmune disorders. However, the long-term implications of such early immune modulation are not fully understood. Potential risks include immune dysregulation, altered disease susceptibility profiles, and developmental or metabolic disturbances. This review synthesizes current evidence on the mechanisms of immune programming during early life, emphasizing the roles of epigenetic changes, trained immunity, and microbiome interactions. It also discusses ethical and regulatory considerations surrounding early-life immunotherapy, especially regarding long-term safety and informed consent. Emerging strategies aimed at enhancing therapeutic precision and minimizing unintended consequences are evaluated. A balanced and personalized approach is crucial to harnessing the full potential of early-life immunotherapies while safeguarding long-term health outcomes.

Keywords: Early-life immunotherapy, immune programming, trained immunity, microbiome, long-term health outcomes.

INTRODUCTION

Early childhood is a critical period for immune system development, characterized by rapid maturation and heightened plasticity of both innate and adaptive immune components [1,2,3,4,5]. During this window, environmental exposures, microbial colonization, nutritional inputs, and immunological interventions can have profound and lasting effects on immune function [6,7,8]. This phase of life presents a unique opportunity to positively shape immune trajectories through targeted immunotherapies, potentially reducing the burden of infectious diseases, allergies, and immune-mediated conditions across the lifespan [9]. Advances in immunotherapeutic modalities including prophylactic and therapeutic vaccines, monoclonal antibodies, cytokine modulators, and microbiome-directed strategies have expanded the scope of early-life interventions [10]. These tools are increasingly being employed in neonatal and pediatric populations not only to prevent acute infections but also to modulate long-term immune responses. For instance, early administration of Bacillus Calmette–Guérin (BCG) or measles vaccines has been associated with non-specific protective effects, while microbiome-based interventions show promise in reducing allergic and inflammatory diseases through gut-immune axis modulation [11,12]. However, the long-term implications of immune programming through early-life interventions remain a subject of active investigation and ethical concern. Immune modulation at this formative stage may lead to unintended consequences such as immune tolerance, chronic inflammation, autoimmunity, or susceptibility shifts to other diseases [13]. Moreover, variability in genetic background, maternal influences, and environmental factors

can affect the efficacy and safety of these interventions [14]. This review synthesizes emerging evidence on the mechanisms, benefits, and potential risks of immunotherapeutic interventions during early life. It aims to provide a comprehensive understanding of how such strategies impact immune programming and long-term health, while highlighting the importance of precision, safety monitoring, and ethical oversight. In doing so, the review contributes to a growing dialogue on optimizing early-life immunotherapy for sustainable, equitable, and safe immunological health outcomes.

Early-Life Immune Development: A Window of Opportunity and Vulnerability

The neonatal and early infant periods represent a dynamic and sensitive phase in immune system development. At birth, the immune system is incompletely developed but highly adaptable, evolving rapidly in response to both endogenous and exogenous stimuli [15]. This period is marked by a delicate balance between protection against pathogens and the establishment of immune tolerance, particularly to maternal antigens, commensal microbes, and dietary components [16]. Innate immunity plays a central role in early-life host defense, as it is the first line of response [17]. However, neonatal innate immune cells, such as neutrophils, monocytes, and dendritic cells, exhibit functional immaturity [18]. They often have reduced microbial killing capacity, impaired antigen presentation, and altered cytokine profiles [19]. These limitations are partially offset by maternal antibodies—primarily immunoglobulin G (IgG)—transferred across the placenta, providing passive protection during the first months of life [20].

The adaptive immune system is likewise immature at birth. T and B lymphocytes are present but functionally naïve [21]. CD4+ T helper cell responses are skewed toward a Th2-dominant profile, limiting the pro-inflammatory Th1 responses necessary for efficient viral and intracellular pathogen control [22]. This Th2 bias helps prevent overactive immune responses that could damage developing tissues but also creates vulnerabilities to certain infections and allergic sensitization [23,24].

A critical modulator of immune development during this period is the establishment of the microbiota [25]. Initial colonization begins at birth and continues to evolve through infancy. The mode of delivery (vaginal vs. cesarean), feeding practices (breastfeeding vs. formula), antibiotic exposure, and environmental factors all influence microbial diversity and stability [26]. This early microbiome profoundly shapes immune maturation through microbial-associated molecular patterns (MAMPs) and metabolites that interact with host immune cells [27].

Immune plasticity during this early period allows for immune training—beneficial adaptation through exposure to microbial and antigenic stimuli—but also poses a risk for maladaptive imprinting [28]. Poorly timed or inappropriate immune exposures can result in persistent immune dysfunction, including allergy, autoimmunity, or chronic inflammation later in life [29].

Thus, early life represents both a window of opportunity for targeted immunotherapeutic interventions and a period of heightened vulnerability. Interventions during this phase must be carefully timed, dosed, and contextualized to promote beneficial immune programming without causing long-term dysregulation [30].

Immunotherapeutic Strategies in Early Life

Multiple immunotherapeutic approaches are currently being explored or implemented in early life to prevent infections, modulate immune responses, and reduce the risk of immune-mediated diseases [31,32]. Each strategy carries specific benefits and potential risks that must be carefully weighed, especially given the heightened sensitivity of the developing immune system.

Vaccines

Vaccination remains the cornerstone of early-life immunotherapy. Vaccines such as BCG, hepatitis B (HepB), and rotavirus have demonstrated robust efficacy in reducing early childhood morbidity and mortality [33]. However, concerns persist regarding immune deviation, rare cases of vaccine-associated autoimmunity, and altered responsiveness to subsequent antigen exposures [34]. Recent innovations include neonatal-specific schedules, novel adjuvants, and mRNA-based platforms tailored for infants [35,36].

Monoclonal Antibodies

Monoclonal antibodies (mAbs) like palivizumab offer immediate passive protection against respiratory syncytial virus (RSV) and are expanding to target other pathogens such as influenza and SARS-CoV-2 [37]. While effective, these therapies may transiently suppress the infant's ability to mount endogenous immune responses and are often associated with high financial costs [38].

Cytokine-Based Therapies

Immune modulation using interleukins, interferons, or granulocyte-macrophage colony-stimulating factor (GM-CSF) is being studied for neonates at risk of immune dysfunction [39]. These approaches aim to enhance host defense but may lead to unintended consequences, including immune imbalance or potential effects on neurodevelopment [40].

Microbiota-Directed Therapies

Probiotics, prebiotics, postbiotics, and fecal microbiota transplantation (FMT) are designed to support gut-immune axis development [41]. They have shown promise in reducing allergic and inflammatory conditions but raise concerns over microbiome instability and horizontal gene transfer [42].

Immune Tolerance Induction

Strategies such as oral immunotherapy and allergen-specific immunotherapy aim to induce tolerance in children with food allergies [43]. While they may offer long-term desensitization, risks include anaphylaxis and the possibility of promoting unwanted immune deviation [44].

Long-Term Risks and Unintended Consequences

While early-life immunotherapies hold substantial promise, they also carry potential long-term risks that must be considered, particularly when interventions are administered during critical windows of immune and neurodevelopment. The immature and highly plastic immune system of neonates and infants can be both positively influenced and adversely affected by immunotherapeutic exposures [45].

One major concern is immune dysregulation, where inappropriate timing, dosing, or type of intervention may disturb the developing immune balance [46]. This can increase susceptibility to immune-mediated conditions such as allergies, asthma, or autoimmune diseases like type 1 diabetes and juvenile idiopathic arthritis [47]. Overactivation of specific immune pathways or inadequate induction of regulatory mechanisms may contribute to these outcomes.

Another risk involves vaccine-induced immune tolerance or hyporesponsiveness, especially when infants are exposed to the same antigens repeatedly or in high doses [48]. This may lead to a dampened immune response to future infections or reduce the effectiveness of booster vaccinations. Such tolerance could also impact the long-term memory capacity of adaptive immune cells.

Altered infection susceptibility is another unintended consequence. Interventions that skew the immune response toward a specific T helper cell axis—such as Th1, Th2, or Th17—may inadvertently suppress other essential immune functions, potentially increasing vulnerability to certain pathogens or reducing cross-protective immunity [49].

Moreover, some immunomodulators carry the risk of developmental toxicity. For example, cytokine-based therapies or high-dose immunosuppressants may interfere with neuroimmune signaling pathways, affecting cognitive development, behavior, and physical growth [50]. The long-term neurodevelopmental effects of these interventions are not yet fully understood and warrant further longitudinal study.

Ultimately, while early-life immunotherapies offer transformative potential, their implementation requires a cautious and evidence-based approach, including personalized risk-benefit assessments and long-term safety monitoring to mitigate adverse outcomes [51]

Ethical, Regulatory, and Societal Considerations

The implementation of early-life immunotherapies raises important ethical, regulatory, and societal challenges that must be addressed to ensure responsible and equitable use. A central ethical issue in pediatric immunotherapy is the matter of informed consent [52]. Since infants and young children lack the capacity to make medical decisions, parents or guardians are tasked with authorizing interventions on their behalf. While this is standard practice in pediatrics, immunotherapies that may influence long-term immune development raise additional concerns about a child's future autonomy [53]. Decisions made in infancy could shape lifelong health trajectories, underscoring the importance of transparent risk-benefit communication, anticipatory guidance, and mechanisms for long-term ethical accountability.

Long-term monitoring and surveillance are essential for evaluating the enduring safety and efficacy of early-life immunotherapeutic interventions [54]. Because some adverse effects may only emerge years or decades later such as autoimmune conditions, chronic inflammation, or neurodevelopmental changes there is a pressing need for well-structured post-approval registries and longitudinal cohort studies [55]. Regulatory bodies must evolve their frameworks to accommodate extended follow-up periods and facilitate data sharing across countries and institutions.

A further concern is equity in access. High-cost immunotherapies, such as monoclonal antibodies or advanced biologics, are often inaccessible in low- and middle-income countries. Even within high-income nations, disparities persist based on geography, socioeconomic status, and healthcare infrastructure. Ensuring universal and equitable access to effective early-life immunotherapies requires global policy coordination, tiered pricing models, and investment in health system strengthening [56].

Future Directions and Recommendations

To optimize the safety, efficacy, and equity of early-life immunotherapy, several strategic innovations are necessary. Personalized immunotherapy represents a promising frontier, in which interventions are tailored based on individual immune phenotypes, genetic risk factors, and environmental exposures. Advances in biomarker discovery and

immunogenetics can enable the identification of children most likely to benefit from specific interventions while minimizing risk.

Emerging systems immunology approaches, integrating genomics, transcriptomics, proteomics, and metabolomics, offer powerful tools for predicting immunologic responses and long-term outcomes. These data-driven strategies can help uncover early signatures of adverse effects, guide precision dosing, and inform the development of next-generation immunotherapies with improved safety profiles.

Equally important is the integration of immunotherapy into broader maternal-child health models. A holistic approach that connects immunotherapeutic strategies with maternal nutrition, breastfeeding support, infection control, and early developmental care can enhance outcomes synergistically. For example, improving maternal immunity and microbiome health may positively influence infant immune programming and reduce the need for aggressive early interventions. Ultimately, the future of early-life immunotherapy depends on cross-disciplinary collaboration among immunologists, pediatricians, bioethicists, policymakers, and patient advocates. By aligning scientific innovation with ethical responsibility and social justice, we can harness the full potential of early immune interventions to promote lifelong health.

CONCLUSION

Early-life immunotherapies present a unique opportunity to positively influence lifelong immune health, offering protection against infections, allergic conditions, and chronic diseases. However, the immunological immaturity and plasticity of infants make them particularly vulnerable to unintended consequences. Achieving a favorable balance between benefit and risk requires carefully timed, individualized interventions supported by robust scientific evidence. Ongoing research, long-term safety monitoring, and ethical oversight are critical to ensure that these strategies are both safe and equitable. As the field advances, integrating immunotherapy into holistic pediatric care will be essential for optimizing long-term health outcomes for all children.

REFERENCES

1. Koury J, Lucero M, Cato C, Chang L, Geiger J, Henry D, et al. Immunotherapies: Exploiting the immune system for cancer treatment. Journal of Immunology Research. 2018;2018:1–16. doi:10.1155/2018/9585614
2. Jain N. The early life education of the immune system: Moms, microbes and (missed) opportunities. Gut Microbes. 2020;12(1):1824564. doi:10.1080/19490976.2020.1824564
3. Varadé J, Magadán S, González-Fernández Á. Human immunology and immunotherapy: main achievements and challenges. Cellular and Molecular Immunology. 2020;18(4):805–28. doi:10.1038/s41423-020-00530-6
4. Olivieri B, Betterle C, Zanoni G. Vaccinations and autoimmune diseases. Vaccines. 2021;9(8):815. doi:10.3390/vaccines9080815
5. Blanco LP, Kaplan MJ. Metabolic alterations of the immune system in the pathogenesis of autoimmune diseases. PLoS Biology. 2023;21(4):e3002084. doi:10.1371/journal.pbio.3002084
6. Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. Science. 2016;352(6285):539–44. doi:10.1126/science.aad9378
7. Kreitinger JM, Beamer CA, Shepherd DM. Environmental Immunology: Lessons Learned from Exposure to a Select Panel of Immunotoxicants. The Journal of Immunology. 2016;196(8):3217–25. doi:10.4049/jimmunol.1502149
8. Mullaney JA, Roy NC, Halliday C, Young W, Altermann E, Kruger MC, et al. Effects of early postnatal life nutritional interventions on immune-microbiome interactions in the gastrointestinal tract and implications for brain development and function. Frontiers in Microbiology. 2022;13. doi:10.3389/fmicb.2022.960492
9. Goenka A, Kollmann TR. Development of immunity in early life. Journal of Infection. 2015;71:S112–20. doi:10.1016/j.jinf.2015.04.027
10. Esmaeilzadeh A, Rostami S, Yeganeh PM, Tahmasebi S, Ahmadi M. Recent advances in antibody-based immunotherapy strategies for COVID-19. Journal of Cellular Biochemistry. 2021;122(10):1389–412. doi:10.1002/jcb.30017
11. Okafor CN, Rewane A, Momodu II. Bacillus calmette Guerin. StatPearls - NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538185/
12. De Jong SE, Olin A, Pulendran B. The impact of the microbiome on immunity to vaccination in humans. Cell Host & Microbe. 2020;28(2):169–79. doi:10.1016/j.chom.2020.06.014
13. Yasmeen F, Pirzada RH, Ahmad B, Choi B, Choi S. Understanding autoimmunity: mechanisms, predisposing factors, and cytokine therapies. International Journal of Molecular Sciences. 2024;25(14):7666. doi:10.3390/ijms25147666
14. Hernandez LM, Blazer DG. Genetics and health. Genes, Behavior, and the Social Environment - NCBI Bookshelf. 2006. Available from: https://www.ncbi.nlm.nih.gov/books/NBK19932/

15. Institute for Quality and Efficiency in Health Care (IQWiG). In brief: The innate and adaptive immune systems. InformedHealth.org - NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279396/
16. Nunez N, Réot L, Menu E. Neonatal immune system ontogeny: the role of maternal microbiota and associated factors. How might the Non-Human Primate model enlighten the path? Vaccines. 2021;9(6):584. doi:10.3390/vaccines9060584
17. Aristizábal B, González Á. Innate immune system. Autoimmunity - NCBI Bookshelf. 2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459455/
18. Tsafaras GP, Ntontsi P, Xanthou G. Advantages and limitations of the neonatal immune system. Frontiers in Pediatrics. 2020;8. doi:10.3389/fped.2020.00005
19. Cuenca A, Wynn J, Moldawer L, Levy O. Role of innate immunity in neonatal infection. American Journal of Perinatology. 2013;30(02):105–12. doi:10.1055/s-0032-1333412
20. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IGG placental transfer in healthy and pathological pregnancies. Clinical and Developmental Immunology. 2012;2012:1–13. doi:10.1155/2012/985646
21. Cano RLE, Lopera HDE. Introduction to T and B lymphocytes. Autoimmunity - NCBI Bookshelf. 2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459471/
22. Howard FHN, Kwan A, Winder N, Mughal A, Collado-Rojas C, Muthana M. Understanding Immune Responses to Viruses—Do underlying TH1/TH2 cell biases predict outcome? Viruses. 2022;14(7):1493. doi:10.3390/v14071493
23. Berger A. Science commentary: Th1 and Th2 responses: what are they? BMJ. 2000;321(7258):424. doi:10.1136/bmj.321.7258.424
24. León B. Understanding the development of Th2 cell-driven allergic airway disease in early life. Frontiers in Allergy. 2023;3. doi:10.3389/falgy.2022.1080153
25. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Research. 2020;30(6):492–506. doi:10.1038/s41422-020-0332-7
26. Inchingolo F, Inchingolo AD, Palumbo I, Trilli I, Guglielmo M, Mancini A, et al. The Impact of cesarean section delivery on Intestinal microbiota: Mechanisms, Consequences, and Perspectives—A Systematic Review. International Journal of Molecular Sciences. 2024;25(2):1055. doi:10.3390/ijms25021055
27. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Research. 2020;30(6):492–506. doi:10.1038/s41422-020-0332-7
28. Coventry BJ, Henneberg M. The Immune System and Responses to Cancer: Coordinated Evolution. F1000Research. 2021;4:552. doi:10.12688/f1000research.6718.3
29. Xiang Y, Zhang M, Jiang D, Su Q, Shi J. The role of inflammation in autoimmune disease: a therapeutic target. Frontiers in Immunology. 2023;14. doi:10.3389/fimmu.2023.1267091
30. Wachs TD, Georgieff M, Cusick S, McEwen BS. Issues in the timing of integrated early interventions: contributions from nutrition, neuroscience, and psychological research. Annals of the New York Academy of Sciences. 2013;1308(1):89–106. doi:10.1111/nyas.12314
31. Qadri H, Shah AH, Alkhanani M, Almilaibary A, Mir MA. Immunotherapies against human bacterial and fungal infectious diseases: A review. Frontiers in Medicine. 2023;10. doi:10.3389/fmed.2023.1135541
32. Yatoo MohdI, Hamid Z, Rather I, Nazir QUA, Bhat RA, Haq AU, et al. Immunotherapies and immunomodulatory approaches in clinical trials - a mini review. Human Vaccines & Immunotherapeutics. 2021;17(7):1897–909. doi:10.1080/21645515.2020.1871295
33. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology. 2020;21(2):83–100. doi:10.1038/s41577-020-00479-7
34. Bhattacharjee B, Lu P, Monteiro VS, Tabachnikova A, Wang K, Hooper WB, et al. Immunological and Antigenic Signatures Associated with Chronic Illnesses after COVID-19 Vaccination. medRxiv. 2025; doi:10.1101/2025.02.18.25322379
35. Fayez NA, Nassar MS, Alshehri AA, Alnefaie MK, Almughem FA, Alshehri BY, et al. Recent advancement in mRNA vaccine development and applications. Pharmaceutics. 2023;15(7):1972. doi:10.3390/pharmaceutics15071972
36. Barman S, Borriello F, Brook B, Pietrasanta C, De Leon M, Sweitzer C, et al. Shaping neonatal immunization by tuning the delivery of synergistic adjuvants via nanocarriers. ACS Chemical Biology. 2022;17(9):2559–71. doi:10.1021/acschembio.2c00497
37. Scotta MC, Stein RT. Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood. Jornal De Pediatria. 2022;99:S4–11. doi:10.1016/j.jped.2022.10.004

38. Malik B, Ghatol A. Understanding how monoclonal antibodies work. StatPearls - NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572118/
39. Borriello F, Galdiero MR, Varricchi G, Loffredo S, Spadaro G, Marone G. Innate immune modulation by GM-CSF and IL-3 in health and disease. International Journal of Molecular Sciences. 2019;20(4):834. doi:10.3390/ijms20040834
40. Bhattacharya P, Thiruppathi M, Elshabrawy HA, Alharshawi K, Kumar P, Prabhakar BS. GM-CSF: An immune modulatory cytokine that can suppress autoimmunity. Cytokine. 2015;75(2):261–71. doi:10.1016/j.cyto.2015.05.030
41. Ciernikova S, Sevcikova A, Drgona L, Mego M. Modulating the gut microbiota by probiotics, prebiotics, postbiotics, and fecal microbiota transplantation: An emerging trend in cancer patient care. Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer. 2023;1878(6):188990. doi:10.1016/j.bbcan.2023.188990
42. Noguera-Fernández N, Candela-González J, Orenes-Piñero E. Probiotics, prebiotics, fecal microbiota transplantation, and dietary patterns in inflammatory bowel disease. Molecular Nutrition & Food Research. 2024;68(18). doi:10.1002/mnfr.202400429
43. Vazquez-Ortiz M, Turner PJ. Improving the safety of oral immunotherapy for food allergy. Pediatric Allergy and Immunology. 2015;27(2):117–25. doi:10.1111/pai.12510
44. Anagnostou A. Weighing the benefits and risks of oral immunotherapy in clinical practice. Allergy and Asthma Proceedings. 2021;42(2):118–23. doi:10.2500/aap.2021.42.200107
45. Yu JC, Khodadadi H, Malik A, Davidson B, Da Silva Lopes Salles É, Bhatia J, et al. Innate immunity of neonates and infants. Frontiers in Immunology. 2018;9. doi:10.3389/fimmu.2018.01759
46. Boasso A, Shearer GM, Chougnet C. Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it? Journal of Internal Medicine. 2008;265(1):78–96. doi:10.1111/j.1365-2796.2008.02043.x
47. D'Auria E, Minutoli M, Colombo A, Sartorio MUA, Zunica F, Zuccotti G, et al. Allergy and autoimmunity in children: non-mutually exclusive diseases. A narrative review. Frontiers in Pediatrics. 2023;11. doi:10.3389/fped.2023.1239365
48. Saso A, Kampmann B. Vaccine responses in newborns. Seminars in Immunopathology. 2017;39(6):627–42. doi:10.1007/s00281-017-0654-9
49. Howard FHN, Kwan A, Winder N, Mughal A, Collado-Rojas C, Muthana M. Understanding Immune Responses to Viruses—Do underlying TH1/TH2 cell biases predict outcome? Viruses. 2022;14(7):1493. doi:10.3390/v14071493
50. Mallick R, Basak S, Chowdhury P, Bhowmik P, Das RK, Banerjee A, et al. Targeting Cytokine-Mediated inflammation in Brain Disorders: Developing new treatment Strategies. Pharmaceuticals. 2025;18(1):104. doi:10.3390/ph18010104
51. Mallick R, Basak S, Chowdhury P, Bhowmik P, Das RK, Banerjee A, et al. Targeting Cytokine-Mediated inflammation in Brain Disorders: Developing new treatment Strategies. Pharmaceuticals. 2025;18(1):104. doi:10.3390/ph18010104
52. Alahmad G. Informed consent in pediatric oncology. Cancer Control. 2018;25(1). doi:10.1177/1073274818773720
53. Stratton K, Wilson CB, McCormick MC. Immunization Safety review: Multiple immunizations and immune dysfunction. Immunization Safety Review - NCBI Bookshelf. 2002. Available from: https://www.ncbi.nlm.nih.gov/books/NBK220494/
54. Nsubuga P, White ME, Thacker SB, Anderson MA, Blount SB, Broome CV, et al. Public Health Surveillance: a tool for targeting and monitoring interventions. Disease Control Priorities in Developing Countries - NCBI Bookshelf. 2006. Available from: https://www.ncbi.nlm.nih.gov/books/NBK11770/
55. Gliklich RE, Leavy MB, Dreyer NA. Patient registries. Registries for Evaluating Patient Outcomes: A User's Guide - NCBI Bookshelf. 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562581/
56. Patel J, More S, Sohani P, Bedarkar S, Dinesh KK, Sharma D, et al. Reshaping the equitable and inclusive access to healthcare: A qualitative study. Clinical Epidemiology and Global Health. 2024;26:101544. doi:10.1016/j.cegh.2024.101544

CITE AS: Zikayo Amulaga R. (2025). Long-Term Immune Programming through Early-Life Immunotherapies: Risks and Benefits. Research Output Journal of Engineering and Scientific Research 4(3): 107-112. https://doi.org/10.59298/ROJESR/2025/4.3.107112